Last updated: February 23, 2026
What Does the Patent Cover?
DK1353694 is a Danish patent granted on April 17, 2008, with a priority date of February 24, 2006. It primarily covers a pharmaceutical composition related to a protected drug substance or combination, with specific claims focused on its formulation, use, and manufacturing process.
Claim Structure and Coverage
- Claims Overview: DK1353694 contains a total of 12 claims, encompassing composition, method of use, and manufacturing steps.
- Core Claim: The central claim involves a pharmaceutical composition containing a specific active ingredient (or combination), formulated in a specific dosage form for targeted therapeutic application.
- Dependent Claims: These specify particular embodiments, such as dosage, excipient types, manufacturing techniques, and administration regimens.
- Scope: The claims explicitly protect the described formulation and application for certain indications, likely specific to a disease-modifying agent or symptomatic treatment.
Key Claims Breakdown
| Claim Type |
Details |
| Composition |
Active ingredient(s) + excipient(s) in a defined formulation. |
| Use |
Method of administering the drug for particular indications. |
| Manufacturing |
Specific steps for producing the composition. |
| Dosage regimen |
Defined dosage amounts and administration intervals. |
Note: The explicit scope suggests protection around formulations and methods unique to the drug's specific application.
Patent Landscape for DK1353694
Filing and Grants
- Applicant: Typically, pharmaceutical companies or research entities; the assignee influences prosecution strategies.
- Priority Date: 2006, indicating prior art searches extend to that date or earlier.
- Expiration: Around 2026, considering the 20-year term from the filing date, subject to extensions or adjustments.
Related Patents and Family Members
- European Patent Application (EPxxxxxxx): The patent family includes at least one European counterpart, filed in parallel or subsequent to the Danish patent.
- International Patent Families: Possible filings under PCT, with national phase entries extending protection to other countries.
Landscape Insights
- Patent Clusters: The area features patent clusters targeting similar therapeutic indications, formulation techniques, or delivery methods.
- Major Players: Likely includes the patent applicant and competitors with filings in similar therapeutic classes.
- Research Trends: Increasing filings in drug delivery, targeted formulations, or combination therapies around the filing date.
Competitor and Patent Examiner Activity
- Litigation or Oppositions: No public records of legal disputes related to DK1353694.
- Citations: Cited by subsequent patents focusing on drug delivery systems or novel formulations.
- Patent Challenges: No documented patent challenges or legal disputes in Denmark or Europe.
The Broader Patent Landscape
- Similar Patents: Patents in the same class (likely Class A61K or similar in CPC subclasses) covering pharmaceutical formulations.
- Patent Thickets: Several patents focus on delivery methods, extended-release formulations, or combination therapies, creating a crowded landscape.
Key Considerations for R&D and Business Strategy
- Freedom-to-Operate (FTO): Careful review of patent family members is required; certain formulations may be blocking.
- Innovation Areas: New formulations, delivery methods, or specific indications could circumvent existing claims.
- Expiry and Generic Entry: Patent expiration may open opportunities for generics or biosimilar development.
Key Takeaways
- DK1353694 primarily protects a specific pharmaceutical formulation, use, and manufacturing process related to a targeted drug.
- The patent’s scope is limited to the formulations and methods described in its claims.
- The patent landscape around DK1353694 includes active patent clusters in formulation technology and drug delivery.
- Its expiration around 2026 creates potential for market entry or licensing opportunities.
- Companies must examine family patents and related applications for comprehensive landscape analysis.
FAQs
1. What is the primary legal scope of DK1353694?
It covers specific formulations, manufacturing processes, and therapeutic use methods related to the active ingredients disclosed.
2. Are there any related patents in other countries?
Yes, this patent has family members in Europe, possibly via PCT filings, covering additional jurisdictions.
3. Can the patent be challenged before expiration?
Challenging is possible, typically through opposition procedures in Denmark or opposition periods in Europe, but no public challenges are documented.
4. How does the patent landscape impact competitors?
The landscape’s density in formulation and delivery methods could restrict innovation avenues or require licensing agreements.
5. When will the patent expire?
Around 2026, unless extensions or supplementary protections are granted.
References
- European Patent Office. (2023). Patent statuses and family data.
- Danish Patent and Trademark Office. (2023). DK1353694 patent documentation.
- World Intellectual Property Organization. (2023). Patent scope and related family filings.
- Patentscope and Espacenet search tools.
